Oncology News | pharmaphorum

News

Update: Orion buys stake in LegoChem as biotech push goes on

Food group Orion Group has taken a 25% in South Korean biotech LegoChem Bioscience, becoming its largest shareholder, as part of a push into the biotech sector.

News

Keytruda breaks new ground in cervical cancer

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/

News

Study finds hundreds of overlooked cancer drug targets

Researchers from the Wellcome Sanger Institute and partners have carried out a comprehensive analysis of cancer cells, identifying 370 ‘priority’ targets that could be use

News

FDA starts review of Lantheus’ generic Lutathera

Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tu

News

UK study backs whole-genome screening for cancer care

A major new study in the UK has shown that combining whole-genome sequencing (WGS) and real-world clinical data at a national scale can help deliver tailored, personalised

News

FDA blocks Astellas’ Claudin cancer drug over manufacturing

Manufacturing problems have scuppered Astellas’ chances of approval in the US this month for zolbetuximab, currently leading the field among Claudin 18.2-targeted drug can

Update: Orion buys stake in LegoChem as biotech push goes on

Keytruda breaks new ground in cervical cancer

Study finds hundreds of overlooked cancer drug targets

FDA starts review of Lantheus’ generic Lutathera

UK study backs whole-genome screening for cancer care

FDA blocks Astellas’ Claudin cancer drug over manufacturing

Making direct-to-patient work, with Matt Wadyka

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks